Nanjing Vazyme Biotech Co Ltd (688105) — Capital Reinvestment Ratio
Nanjing Vazyme Biotech Co Ltd (688105) has a Capital Reinvestment Ratio of 0.21x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥75.30 Million) in capital expenditures (CN¥15.83 Million). See free cash flow generation of Nanjing Vazyme Biotech Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nanjing Vazyme Biotech Co Ltd Capital Reinvestment Ratio (2019–2025)
This chart tracks Nanjing Vazyme Biotech Co Ltd's Capital Reinvestment Ratio across 6 annual periods.
Annual Capital Reinvestment Ratio for Nanjing Vazyme Biotech Co Ltd (2019–2025)
Year-by-year Capital Reinvestment Ratio for Nanjing Vazyme Biotech Co Ltd from 2019 to 2025. For live market cap and broader valuation context, see Nanjing Vazyme Biotech Co Ltd (688105) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | CN¥233.16 Million | CN¥47.39 Million | ▼ -82.7% |
| 2023 | 1.17x | CN¥198.40 Million | CN¥232.90 Million | ▼ -10.4% |
| 2022 | 1.31x | CN¥735.17 Million | CN¥962.86 Million | ▲ +208.4% |
| 2021 | 0.42x | CN¥616.80 Million | CN¥261.96 Million | ▲ +123.7% |
| 2020 | 0.19x | CN¥803.55 Million | CN¥152.54 Million | ▼ -85.5% |
| 2019 | 1.31x | CN¥15.20 Million | CN¥19.88 Million | — |